Literature DB >> 22820513

Immune deficiency and autoimmunity.

Thomas Prescott Atkinson1.   

Abstract

PURPOSE OF REVIEW: To provide an overview of the mechanisms of autoimmunity associated with primary immunodeficiencies. RECENT
FINDINGS: Over the past several years, new concepts of the relationship between primary immunodeficiencies and autoimmunity have developed that promise to illuminate the mechanisms by which alterations in the same gene may alternately, or sometimes concomitantly, lead to increased susceptibility to infection and loss of self-tolerance. A common pathway in the process leading to autoimmunity involves gene defects that permit effector T-cell development in the absence of sufficient regulatory T-cell function. Conversely, gene defects that primarily lead to autoimmunity may impair host defense by neutralizing key elements of immunity. The production of neutralizing antibodies against cytokines comprises a newly recognized mechanism in which autoimmunity may lead to immunodeficiency.
SUMMARY: Autoimmunity has long been known to be a part of the presenting symptoms and clinical course of many primary immunodeficiencies. This review will provide an overview of the new concepts regarding the complex relationship between the genetic immune deficiencies and autoimmunity. The mechanisms by which immunodeficiency may lead to autoimmunity or, in some instances, by which autoimmunity produces immunodeficiency can provide important insights into the underlying pathogenic processes and ultimately better diagnosis and treatment for the patient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820513     DOI: 10.1097/BOR.0b013e32835680c6

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  10 in total

1.  Interleukin-2 Receptor β Thr-450 Phosphorylation Is a Positive Regulator for Receptor Complex Stability and Activation of Signaling Molecules.

Authors:  Blanca E Ruiz-Medina; Jeremy A Ross; Robert A Kirken
Journal:  J Biol Chem       Date:  2015-07-07       Impact factor: 5.157

Review 2.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 3.  Rheumatologic manifestations of primary immunodeficiency diseases.

Authors:  V R Dimitriades; R Sorensen
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

Review 4.  Autoimmunity in immunodeficiency.

Authors:  Krista Todoric; Jessica B Koontz; Daniel Mattox; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

5.  Immunostimulating effects of extract of Acanthopanax sessiliflorus.

Authors:  Jung-Hoon Kim; Eun-Hye Shin; Hak-Yong Lee; Bong-Gun Lee; Sang-Hoon Park; Dae-In Moon; Gyo-Chang Goo; Dae-Young Kwon; Hye-Jeong Yang; Ok-Jin Kim; Hong-Geun Oh
Journal:  Exp Anim       Date:  2013

6.  The Prevalence of S. aureus Skin and Soft Tissue Infections in Patients with Pemphigus.

Authors:  Zeinab Fagheei Aghmiyuni; Ahmad Khorshidi; Rezvan Moniri; Tahereh Soori; Seyed Gholam Abbas Musavi
Journal:  Autoimmune Dis       Date:  2016-10-09

7.  Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation.

Authors:  Michael Bitar; Andreas Boldt; Marie-Theres Freitag; Bernd Gruhn; Ulrike Köhl; Ulrich Sack
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

8.  Pemphigus vulgaris and infections: a retrospective study on 155 patients.

Authors:  Nafiseh Esmaili; Hossein Mortazavi; Pedram Noormohammadpour; Majid Boreiri; Tahereh Soori; Iman Vasheghani Farahani; Mitra Mohit
Journal:  Autoimmune Dis       Date:  2013-06-13

9.  Targeting Antigens to Dec-205 on Dendritic Cells Induces Immune Protection in Experimental Colitis in Mice.

Authors:  Munisch Wadwa; Robert Klopfleisch; Jan Buer; Astrid M Westendorf
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2016-01-27

10.  Bank1 and NF-kappaB as key regulators in anti-nucleolar antibody development.

Authors:  Hammoudi Alkaissi; Said Havarinasab; Jesper Bo Nielsen; Peter Söderkvist; Per Hultman
Journal:  PLoS One       Date:  2018-07-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.